ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
तुलना करने के लिए मीट्रिक्स | PROK | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPROKपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.5x | −1.3x | −0.5x | |
PEG अनुपात | −0.24 | −0.09 | 0.00 | |
क़ीमत/बुक | −0.7x | 5.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 737.0x | 9.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 175.8% | 86.2% | 43.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.5% | 4.9% | अनलॉक करें |